Bone scan can be spared in asymptomatic prostate cancer patients with psa of ≤20 ng/ml and gleason score of ≤6 at the initial stage of diagnosis

Japanese Journal of Clinical Oncology

Volumn 41, Issue 10, 2011, Pages 1209-1213

  Tanaka, Nobumichi ^a   Fujimoto, Kiyohide ^a   Shinkai, Takayuki ^a   Nakai, Yasushi ^a   Kuwada, Masaomi ^a   Anai, Satoshi ^a   Miyake, Makito ^a   Hirayama, Akihide ^a   Hasegawa, Masatoshi ^a   Hirao, Yoshihiko ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bone metastases; Bone scan; Guideline; Prostate cancer; Staging

Indexed keywords

MEDRONIC ACID; PROSTATE SPECIFIC ANTIGEN; TECHNETIUM 99M;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PROSTATE CANCER; RISK FACTOR;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; HUMANS; JAPAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 80053525327     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyr118     Document Type: Article

References (16)

1. Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schönitzer D, et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001;58:417-24.
2. Cooperberg MR, Cowan J, Broering JM, Carroll PR. High-risk prostate cancer in the United States, 1990-2007. World J Urol 2008;26:211-8.
3. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007;178:S14-9.
4. Tanaka N, Fujimoto K, Hirayama A, Yoneda T, Yoshida K, Hirao Y. Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG data. Jpn J Clin Oncol 2010;40:588-92.
5. EAU Guidelines, 2010. http://www.uroweb.org/guidelines/.
6. NCCN Clinical Practice Guidelines in OncologyTM, Prostate Cancer Early Detection V.2.2010. www.nccn.org.
7. Briganti A, Passoni N, Ferrari M, Capitanio U, Suardi N, Gallina A, et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool. Eur Urol 2010;57:551-8.
8. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007;177:2106-31.
9. Hricak H, Choyke PL, Eberhardt SC, Leibel SA, Scardino PT. Imaging prostate cancer: a multidisciplinary perspective. Radiology 2007;243:28-53.
10. Sobin LH, Wittekind CH. TNM Classification of Malignant Tumors. 6th edn. Wiley-Liss Inc., New York; 2002.
11. Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 1991;145:313-8.
12. Wolff JM, Zimny M, Borchers H, Wildberger J, Buell U, Jakse G. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? Eur Urol 1998;33:376-81.
13. Bruwer G, Heyns CF, Allen FJ. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate. Eur Urol 1999;35:223-7.
14. Lee N, Fawaaz R, Olsson CA, Benson MC, Petrylak DP, Schiff PB, et al. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat Oncol Biol Phys 2000;48:1443-6.
15. Kosuda S, Yoshimura I, Aizawa T, Koizumi K, Akakura K, Kuyama J, et al. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan. Cancer 2002;94:964-72.
16. Brimo F, Schultz L, Epstein JI. The value of mandatory second opinion pathology review of prostate needle biopsy interpretation before radical prostatectomy. J Urol 2010;184:126-30.